Tan Yu Guang, Allen John Carson, Tay Kae Jack, Huang Hong Hong, Lee Lui Shiong
Department of Urology, Sengkang General Hospital, Singapore.
Department of Urology, Singapore General Hospital, Singapore.
Int J Urol. 2020 Sep;27(9):783-788. doi: 10.1111/iju.14300. Epub 2020 Jul 7.
To compare the perioperative and oncological outcomes between robot-assisted radical cystectomy with intracorporeal urinary diversion versus open cystectomy for bladder cancer in a contemporary Enhanced Recovery After Surgery cohort.
All consecutive patients who underwent radical cystectomy and managed under an Enhanced Recovery After Surgery protocol, from December 2013 to October 2018, were reviewed. Propensity score adjustment was carried out to reduce biases attributable to covariate imbalances.
There were 19 robot-assisted radical cystectomy with intracorporeal urinary diversion and 21 open cystectomy patients. The robot-assisted radical cystectomy with intracorporeal urinary diversion cohort was associated with lower estimated blood loss (397 vs 787 mL, P = 0.05), with a trend toward shorter duration of ileus and postoperative opioid administration. These benefits were apparent, despite a longer operative time (581 vs 446 mins, P = 0.03), a higher proportion of orthotopic bladder reconstruction (26.3 vs 9.5%, P = 0.08), a more prevalent use of neoadjuvant chemotherapy and a higher number of salvage cystectomies for the robot-assisted radical cystectomy with intracorporeal urinary diversion group. Comparable perioperative complications and length of hospital stay were observed. The pathological and intermediate oncological outcomes were similar in both groups (locally advanced disease: 52.6 vs 47.6%, P = 0.85; lymph node yield: 29 vs 34, P = 0.23). The mean recurrence-free survival and overall survival in the robot-assisted radical cystectomy with intracorporeal urinary diversion group was 37.5 and 43.0 months, respectively, compared with 21.4 (P = 0.09) and 35.5 (P = 0.14) months, respectively, in open cystectomy.
Robot-assisted radical cystectomy with intracorporeal urinary diversion has perioperative benefits of lower estimated blood loss, with a trend toward faster bowel recovery and a shorter duration of opioid analgesia when compared with open cystectomy. Robot-assisted radical cystectomy with intracorporeal urinary diversion also achieves similar intermediate-term oncological and survival outcomes.
在当代术后加速康复队列中,比较机器人辅助根治性膀胱切除术联合体内尿流改道术与开放性膀胱切除术治疗膀胱癌的围手术期及肿瘤学结局。
回顾了2013年12月至2018年10月期间所有接受根治性膀胱切除术并按照术后加速康复方案进行管理的连续患者。进行倾向评分调整以减少因协变量不平衡导致的偏差。
有19例接受机器人辅助根治性膀胱切除术联合体内尿流改道术的患者和21例接受开放性膀胱切除术的患者。机器人辅助根治性膀胱切除术联合体内尿流改道术组的估计失血量较低(397 vs 787 mL,P = 0.05),肠梗阻持续时间和术后阿片类药物使用时间有缩短趋势。尽管机器人辅助根治性膀胱切除术联合体内尿流改道术组的手术时间较长(581 vs 446分钟,P = 0.03),原位膀胱重建比例较高(26.3% vs 9.5%,P = 0.08),新辅助化疗的使用更为普遍,挽救性膀胱切除术的数量更多,但这些益处仍然明显。观察到两组围手术期并发症和住院时间相当。两组的病理及中期肿瘤学结局相似(局部晚期疾病:52.6% vs 47.6%,P = 0.85;淋巴结获取数量:29 vs 34,P = 0.23)。机器人辅助根治性膀胱切除术联合体内尿流改道术组的平均无复发生存期和总生存期分别为37.5个月和43.0个月,而开放性膀胱切除术组分别为21.4个月(P = 0.09)和35.5个月(P = 0.14)。
与开放性膀胱切除术相比,机器人辅助根治性膀胱切除术联合体内尿流改道术具有围手术期估计失血量较低的益处,肠道恢复更快且阿片类镇痛时间更短。机器人辅助根治性膀胱切除术联合体内尿流改道术也能实现相似的中期肿瘤学和生存结局。